Aim of the study is to compare the everolimus eluting stent and sirolimus eluting stent in all comers PCI eligible patients
Compared with the currently available first-generation drug-eluting stents (DES), second-generation DES have been designed with the goal of improving safety and efficacy. Everolimus, a sirolimus analogue, is released from a open cell, thin-strut, cobalt-chromium frame. A significant reduction in cardiac events was noted in patients with the everolimus-eluting stent compared with those who had a paclitaxel-eluting stent. Sirolimus eluting stent was the first available drug eluting stent and is the most tested. Therefore the investigators compared the safety and efficacy of the everolimus-eluting and sirolimus eluting stents in unselected patients in real world practice.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
600
coronary angioplasty with stent implantation
coronary angioplasty with stent implantation
Division of Cardiology Aorn Moscati
Avellino, Italy
Target Vessel Revascularization
Incidence of clinically driven target vessel revascularization at 2 year follow up
Time frame: 2 year
cardiac death
incidence of death for cardiac causes at 2 year
Time frame: 2 year
non fatal myocardial infarction
incidence of non fatal Q or non Q wave reinfarction at 2 year
Time frame: 2 year
stent thrombosis
incidence of definite, probable or possible stent thrombosis at 2 year
Time frame: 2 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.